We use cookies to provide you with a better experience. By clicking the Accept button, you are agreeing to our use of cookies in accordance with our Privacy Policy.
  • Patient Resources
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
    • Glossary
  • Professional Resources
    • Research Center Profiles
    • Industry Provider Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
  • About Us
  • Contact Us
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NIH finalizes changes in conflict of interest rules

NIH finalizes changes in conflict of interest rules

August 24, 2011
CenterWatch Staff

The National Institutes of Health has finalized rules to reduce financial conflicts of interests among federally funded researchers who also receive payments or stock from drug and medical device companies, according to a report by the Washington Post.

The rules, which will affect more than 40,000 researchers, come after a string of high profile cases in which federally funded researchers failed to disclose millions of dollars from companies with a financial interest in the outcome of their work.

Researchers who receive more than $5,000 in income from drug or device companies must disclose the payments. Universities or other institutions employing the researchers must collect the data and provide for public access to it.

Institutions will not be forced to disclose conflict-of-interest information online. Instead, they may maintain the data offline and provide it only when requested.

This change reduces the administrative burden of the proposed public disclosure rule for institutions employing federally funded researchers, said Sally Rockey, the NIH’s deputy director for extramural research.

Universities also will be required to develop plans to manage the financial conflicts of individual researchers, but the plans do not have to be made public.

Praising the “vast majority of researchers” as ethical and sensitive to conflicts of interest, NIH director Francis S. Collins called the new rules “an insurance plan against potential trouble downstream.” Collins added that the rules will ensure that government-funded researchers can continue working with private companies.

“We depend critically on those [relationships] for advances in biomedical research, but we do want to make sure. that the highest standards of transparency and integrity are maintained,” Collins said.

This announcement completes the first updating of the conflict-of-interest rules since 1995. As before, violations may be punished by suspension or termination of research funding.

“They’re playing hide the ball on this,” said Paul Thacker, an investigator with the nonprofit Project on Government Oversight. He said all conflict-of-interest information should be published online. “The take-home message is that these are half steps. [NIH] could have taken steps that ensured the trust of American taxpayers who are funding this research, but they chose not to take those steps.”

The issue of corporate payments to medical researchers has exploded in recent years. In an influential 2009 report, the Institute of Medicine said such conflicts “threaten the integrity of scientific investigations.”

United States Ethics/Regulatory

Upcoming Events

  • 16Dec

    Master the Regulatory Pathway for Cell & Gene Therapy Submissions: Strategies for Successful BLAs

Featured Products

  • Regenerative-medicine-steps-to-accelerate-development-pdf

    Regenerative Medicine: Steps to Accelerate Development — PDF

  • Clinical-trial-agreements-a-guide-to-key-words-and-phrases-pdf

    Clinical Trial Agreements: A Guide to Key Words and Phrases — PDF

Featured Stories

  • Ich_logo

    ICH Overhauls 22-Year-Old Clinical Studies Guideline

  • Survey_chart2019

    Sponsors, CROs Doing Better, Sites Say, But More Work Is Needed

  • China-360x240

    U.S. Tops List of Trial Startups With China Making Progress in Phase 1

  • Phoneapp-360x240

    Device Apps Present Unique Risks in Trials

New!

2019 Site Survey Reports

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing